RE:RE:RE:RE:Biogen’s $7.3 Bln acquisition of Reata followed bidding warONC/Ys potential value, vs trading price.
Most who tak the time to understand, including the PanCan people who put up $5Million towards an additional arm of Pancratic cancer.
And Roche who will be co-therapy in the Pahse 3 trial ( Panc cancer) ...have done massive due dilligence before geting to this stage.
The existin trading price has little to zero semblance to ultimate "value"
1. The stock has a 60% short holding...that drive the price down.
2. The overall market in is the gutter. Yes not every single company,but many well manged & profitable, dividend payiing companies are way down right now.
3. There has been a plethora of delays from ONC & its expcted milestones & dates.
All of the above bad for any stock.
However to say, becuase it is down today "means it will always be down" is a faulse narative.
Straight up!
If/when they launch phase 3 the SP will be higher.
If/when they announce a phase 3 partner the SP will be higher.
A buy-out....obviously much more.
Recall an institution recently put up $17 million, with an opportunity for more at a higher level.
IM long in the tooth with waiting. However, lways revert back to the science.
If they get apporved. $1.2 billion/year in sales for Panc alone.
Alternatively if they dont, not much hope.
The Next presentaion is in 18 days. News will be out before that. Hopefully good news.